Piramal Pharma Solutions (PPS) has partnered with BerGenBio ASA on the development of bemcentinib for the treatment of elderly patients with relapsed Acute Myeloid Leukemia (AML). Bemcentinib was recently granted Fast Track designation by the U.S. FDA, as there are currently no marketed drugs specifically approved for relapsed AML patients, representing a significant unmet medical need.   Peter DeYoung, chief executive officer, Piramal Pharma Solutions, said, “BerGenBio’s decision to partner w...